Company Overview: Ritter Pharmaceuticals

Industry News

13 Feb

Ritter Pharmaceuticals Announces Collaboration with University of British Columbia to Explore Development of Microbiome Therapeutics in Environmental Enteropathy

LOS ANGELES, CA–(Marketwired – Feb 13, 2017) – Ritter Pharmaceuticals, Inc. ( NASDAQ : RTTR ) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it is collaborating with Dr. B Brett Finlay from...

Read more

26 Jul

Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. We are advancing human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality of gut modulation into applications intended to have a meaningful impact on...

Read more

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address